Suggested remit: To appraise the clinical and cost effectiveness of vibegron within its marketing authorisation for treating symptoms of overactive bladder.
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process Cost Comparison Standard
ID number 6300

Project Team

Project lead Jeremy Powell

Email enquiries

External Assessment Group BMJ Technology Assessment Group (BMJ-TAG), BMJ


Companies sponsors Pierre Fabre (vibegron)
Others Department of Health and Social Care
  NHS England
Patient carer groups Bladder and Bowel Community
  Bladder and Bowel UK
  Bladder Health UK
  Cystitis and Overactive Bladder Foundation
  Kidney Care UK
  Kidney Patient Involvement Network
  Kidney Research UK
  National Kidney Federation
  South Asian Health Foundation
  Specialised Healthcare Alliance
Professional groups Association for Continence Advice
  Association of British Neurologists
  Association of Renal Technologists Physicians
  British Association of Urological Nurses
  British Association of Urological Surgeons
  British Geriatrics Society
  British Society of Urogynaecology
  National Neuroscience Advisory Group
  Royal College of Emergency Medicine
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Obstetricians and Gynaecologists
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society for DGH Nephrologists
  Society for Vascular Nurses
  The Urology Foundation
  UK Clinical Pharmacy Association
  UK Renal Pharmacy Group
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies Aristo Pharma (fesoterodine)
  Aspire Pharma (darifenacin, fesoterodine, solifenacin, tolterodine)
  Astellas Pharma (mirabegron, solifenacin)
  Aurobindo Pharma – Milpharm (solifenacin)
  Brillpharma (oxybutynin)
  Brown & Burk (solifenacin)
  Celix Pharma (fesoterodine, solifenacin)
  Dr. Reddy's Laboratories (fesoterodine)
  Genus Pharmaceuticals (fesoterodine, solifenacin)
  Ennogen Healthcare (propiverine)
  Glenmark Pharmaceuticals (solifenacin, trospium)
  Krka (solifenacin)
  Medical Valley Invest (fesoterodine)
  MSN Laboratories (solifenacin)
  Neon Healthcare (oxybutynin)
  Northumbria Pharma (tolterodine)
  Pfizer (fesoterodine)
  Ranbaxy, a Sun Pharmaceutical Company (solifenacin)
  Roma Pharmaceuticals (oxybutynin)
  Sandoz (solifenacin, tolterodine)
  Strides Pharma (oxybutynin)
  Tillomed Laboratories (oxybutynin, solifenacin)
  Viatris (tolterodine, trospium)
  Zentiva (fesoterodine, oxybutynin, solifenacin, tolterodine)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group
  Cochrane UK
  Cochrane Urology
  Genomics England
  MRC Clinical Trials Unit
  National Institute for Health Research
  The Society for Research in Rehabilitation
  Wellcome Trust


Key events during the development of the guidance:

Date Update
01 March 2024 Invitation to participate
12 September 2023 - 10 October 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6300
03 August 2023 In progress. DHSC referral received
15 May 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual